

HOSTED BY



ELSEVIER

Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Medicine

journal homepage: <http://ees.elsevier.com/apjtm>Original research <http://dx.doi.org/10.1016/j.apjtm.2016.01.017>

Immunological evidence of Zika virus transmission in Thailand

Nitwara Wikan¹, Yupin Suputtamongkol², Sutee Yoksan¹, Duncan R. Smith^{1*}, Prasert Auewarakul²¹Institute of Molecular Biosciences, Mahidol University, Bangkok, Thailand²Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

ARTICLE INFO

Article history:

Received 25 Jun 2015

Received in revised form 25 Jul 2015

Accepted 25 Aug 2015

Available online 13 Jan 2016

Keywords:

Emerging infectious diseases

Serosurvey

Thailand

Zika virus

ABSTRACT

Objective: To identify immunological evidence of Zika virus transmission in Thailand.**Methods:** To undertake a preliminary serosurvey of possible exposure to Zika virus, 21 serum samples from cohort of acute undifferentiated fever patients were examined for immunoreactivity to Zika, Dengue, Japanese encephalitis and Chikungunya envelope antigens by Western blot analysis.**Results:** Twenty of the 21 serum samples showed immunoreactivity to at least one of the antigens, with seven samples showing immunoreactivity to all antigens. Of particular note, two serum samples showed immunoreactivity only to Zika envelope antigen, with no immunoreactivity to other envelope antigens.**Conclusions:** This study presents the first evidence of Zika virus transmission in Thailand, although as yet the relationship between transmission and possible cases of Zika fever in Thailand requires further investigation.

1. Introduction

The family *Flavivirus* within the genus *Flaviviridae* contains some of the most important mosquito transmitted viruses that affect humans and animals. Particularly important mosquito transmitted viruses in this family include Dengue virus (DENV), Yellow fever virus, Japanese encephalitis virus (JEV) and West Nile virus, which combined cause millions of infections every year around the world. However, many of the other viruses in this family also cause disease in humans or animals, but are generally believed to have a more limited geographical range and to cause few infections annually [1].

The mosquito transmitted Zika virus (family *Flavivirus*, genus *Flaviviridae*) was first isolated from a sentinel monkey in the Zika forest near Entebbe, Uganda [2], and the first reported cases of human infection occurred in Nigeria in 1954 [3]. Since then, significant outbreaks of Zika disease have occurred

in Yap Island in the Federated States of Micronesia, and more recently in French Polynesia and New Caledonia with this last outbreak causing more than 8000 suspected cases [4]. Isolated cases have been reported from the Philippines [5], Cambodia [6] and Indonesia [7,8] and autochthonous transmission of Zika has been reported in Brazil [9]. The virus has additionally been detected in mosquitoes in Malaysia [10], and in travelers returning from Malaysia [11] and Thailand [12,13]. However, there have been no direct reports of Zika fever in the Thai population.

The main vector of Zika virus in Africa is the *Aedes africanus* mosquito [14], but *Aedes aegypti* mosquitoes, the main vector of dengue in much of Southeast Asia and elsewhere, are also capable of transmitting Zika virus [15] and it is probable that other *Aedes* species such as *Aedes albopictus*, *Aedes polynesiensis* and *Aedes hensilli* are also capable of transmitting Zika virus to humans [16].

Zika fever has significant similarities with dengue fever, although there is no abrupt clinical onset. The main symptoms are fever, rash, headache, muscle and joint pain, edema of the hands and feet and non-purulent conjunctivitis [17–19]. While the course of the disease is believed to be relatively self-limiting, lasting some 4 d–7 d, the recent outbreak in French Polynesia was marked by a number of cases of Guillain-Barre syndrome as well as other complications after the initial Zika virus infection [20].

*Corresponding author: Duncan R. Smith, Institute of Molecular Biosciences, Mahidol University, Salaya Campus, 25/25 Phuttamonthon Sai 4, Nakorn Pathom 73170, Thailand.

Tel: +66 (662) 441 9003 7

Fax: +66 (662) 441 9906

E-mail: duncan_r_smith@hotmail.com

Peer review under responsibility of Hainan Medical College.

Foundation project: This work was supported by Mahidol University and the Thailand Research Fund (RTA5780009 and IRG5780009). NW is supported by a Mahidol University Post-Doctoral Fellowship.

Given the general similarity of Zika fever to Dengue fever (sudden onset of fever, headache, rash), it is possible that cases of Zika disease remain unreported in Thailand as a consequence of a mis-identification of the disease as dengue fever, compounded by the lack of specific investigation for Zika fever. The well known cross reaction of antibodies between flaviviruses could cause Zika infections to be serologically diagnosed as dengue fever [21].

We have therefore undertaken a preliminary retrospective serosurvey of 21 serum samples from a previously described cohort of acute undifferentiated fever patients collected in Thailand [22] to determine if there is any evidence of exposure to Zika virus.

2. Materials and methods

2.1. Serum samples

The serum samples used in this study were collected as part of a previously described prospective hospital based study on adult patients with acute undifferentiated fever undertaken at a hospital in Nakhon Ratchasima province in Northeastern Thailand [22]. The study was approved by appropriate Ethical Review subcommittees and written informed consent was obtained from all study participants as previously documented [22].

2.2. Synthetic gene construction

The entire *capsid (C)*, *premembrane/membrane (prM)*, and *envelope (E)* gene sequence for Zika virus was commercially synthesized (GeneScript, USA Inc.) based on the sequence of a Cambodian isolate of Zika virus (isolate FSS13025), Genbank number AFD30972.1. The Zika synthetic gene was codon-optimized for efficient expression in mammalian cells. The Zika synthetic clone contained 2385 bp of *C*, *prM*, *E* of Zika virus in the pUC57 plasmid vector.

A DNA fragment containing 19 amino acids of the capsid region immediately upstream of *prM*, as well as the *prM* and *E* sequences was amplified from the codon optimized construct using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific, Waltham, MA) with *NheI*-19CprME-Zika-Fw forward primer (5'-GAGCTAGCCACCATGGGAAGAGGGACCGATACAAGC-3') and 19CprME-Zika-*EcoRI*-Rw reverse primer (5'-CGGAATTCTTATGCGGACACTGCGGTGGA-CAGAAA-3'). After double digestion with *NheI* and *EcoRI* restriction enzymes the product was ligated into *NheI* and *EcoRI* double digested pCDNATM3.1(+) vector. The ligated products were transformed into competent DH5- α *Escherichia coli*. After confirmation of the sequence by DNA sequence analysis, 3 μ g of the pCDNA3.1+_19CprME-Zika plasmid was transfected into 1.3×10^6 cells of HEK293T/17 cells in 6-well plate by the CaCl₂ method. Cells were cultured in Opti-MEM and the culture supernatant was collected at 2 d post-transfection.

2.3. Viral infection

HEK293T/17 cells were infected with either Chikungunya virus (CHIKV) E1: 226V (ECSA: Thai isolate), DENV-2 (16681) or JEV (BJ-1) at MOI of 1 according to our standard

protocols [23–25] and cultured in Opti-MEM for two days after which the culture supernatant was collected.

2.4. Western blot analysis

Opti-MEM, culture supernatant from the pCDNA3.1+_19CprME-Zika transfection and culture supernatants from CHIKV, DENV-2 and JEV infections were resuspended in a non-reducing loading dye and electrophoresed through 10% SDS-PAGE gels with a protein marker (161-0373, precision plus proteinTM all blue prestained standards). Proteins were transferred onto nitrocellulose membranes (HybondTM ECLTM code: RPN303D, GE Healthcare, Little Chalfont, UK). The membranes were blocked with 5% skim milk for 1 h and incubated with following antibodies; a 1:1000 dilution of HB112 (a mouse monoclonal anti-flavivirus group antigen antibody [26]), a 1:1000 dilution of a mouse monoclonal anti-Alphavirus antibody (sc-58088, Santa Cruz Biotechnology, Santa Cruz, USA) or a 1:1000 dilution of human serum for 1 h. After washing, membranes were incubated for 1 h with an appropriate secondary antibody, namely either a HRP-conjugated rabbit anti-mouse IgG (A9044, Sigma St. Louis, USA) or a HRP-conjugated goat anti-human IgG (62-8420, Thermo Fisher Scientific). The membranes were washed and incubated with chemiluminescent substrate (RPN2232, GE Healthcare) prior detecting the signal by the chemiluminescent Western blot imaging system Azure c400.

3. Results

A synthetic gene construct containing the codon optimized sequence of a recently reported Cambodian Zika virus isolate (Genbank number AFD30972.1) encompassing the last 19 codons of the *C* sequence and the *prM* and *E* genes was transfected into HEK293T/17 cells and the supernatant collected on day two post transfection. In parallel HEK293T/17 cells were infected with CHIKV, JEV or DENV-2 and supernatants were collected on day two post infection. Aliquots of these supernatants were electrophoresed through standard SDS-PAGE gels, and the proteins were transferred to nitrocellulose membranes. A total of 26 filters were prepared. Five of the filters were used in control Western blots with a mouse monoclonal pan flavivirus antibody (HB112), with an anti-alphavirus antibody, a combination of both antibodies and with two secondary antibodies (a rabbit anti-mouse IgG and a goat anti-human IgG). Results (Figure 1) show the pan-flavivirus antibody was able to detect Zika, DENV and JEV envelope antigens with no cross reactivity to CHIKV envelope antigen, while conversely the anti-alphavirus antibody was able to detect CHIKV envelope antigen with no cross reactivity to the flaviviruses (Zika, DENV and JEV). The two secondary antibodies showed no immunoreactivity to any of the envelope antigens. Equivalent filters were then used in western blot analyses with 21 serum samples individually. Results showed a complex pattern of immunoreactivity (Table 1 and Figure 1). Only 1 sample showed no immunoreactivity with any of the antigens. Immunoreactivity to the CHIKV envelope antigen was seen in 13/21 (61%) of samples, while the corresponding figures for JEV, Zika and DENV envelope antigens were 14/21 (66%), 16/21 (76%) and 17/21 (80%) respectively. A total of 7 samples showed immunoreactivity to all antigens.




Figure 1. Representative western blots.

Nitrocellulose filters with CHIKV (C) Zika (Z) DENV (D) and JEV (J) envelope antigens were incubated with a pan-flavivirus monoclonal antibody (HB112), an anti-alphavirus monoclonal antibody (alphavirus) or a combination of both (HB112 + Alphavirus) or the respective secondary antibodies alone (Rabbit anti-mouse IgG-HRP and goat anti-human IgG-HRP) or with human serum (S2, S12 and S6). Serum sample S6 shows immunoreactivity to Zika only.

Table 1

Summary of immunoreactivity to 4 arboviral antigens.

Serum	O	CHIKV	Zika	DENV	JEV
S1	-	-	+	+	+
S2	-	+	+	+	+
S3	-	+	+	+	-
S4	-	+	-	+	-
S5	-	+	+	+	+
S6	-	-	+	-	-
S7	-	+	+	+	-
S8	-	+	+	+	+
S9	-	+	+	-	+
S10	-	-	-	-	-
S11	-	+	+	+	-
S12	-	-	+	+	+
S13	-	-	+	+	+
S14	-	+	+	+	+
S15	-	+	+	+	+
S16	-	-	+	-	-
S17	-	-	-	+	+
S18	-	-	-	+	+
S19	-	+	+	+	+
S20	-	+	-	+	+
S21	-	+	+	+	+
Total	0	13	16	17	14

+ Immunoreactivity; - No immunoreactivity detected.

Importantly, 2 samples showed immunoreactivity to only the Zika envelope antigen.

4. Discussion

Dengue is endemic in Thailand, and studies have shown that DENV neutralizing antibodies can be found in more than 95% of the Thai population [27]. Similarly, Thailand introduced a JEV vaccination campaign in 1990, some 25 y ago [28] although JEV remains an important cause of encephalitis in Thailand [29]. As such, the high level of immunoreactivity to DENV and JEV envelope antigens is unsurprising. However, as a consequence of either DENV infection or JEV vaccination/infection both

neutralizing and broadly cross reactive antibodies are generated [30]. An original concern of this study was that anti Zika envelope immunoreactivity seen in the samples would occur as a consequence of cross reactive anti-DENV or anti-JEV antibodies, as has been observed by others [21]. However, in two cases immunoreactivity to only the Zika envelope antigen was observed, strongly suggesting that this is bone fide immunoreactivity to Zika envelope antigen, and not a consequence of cross-reactivity of antibodies from either DENV infection or JEV vaccination/infection.

The levels of immunoreactivity to the CHIKV envelope antigen were somewhat surprising. While there was a large outbreak of CHIKV in Thailand in 2009/2010, this was largely confined to the southern part of Thailand, while the samples in this cohort came from a study undertaken in the Northeastern part of Thailand. However, it has been shown that CHIKV neutralizing antibodies are extremely long lasting [31], and Thailand has had outbreaks of CHIKV before the 2009/2010 outbreak as a consequence of circulation of the indigenous Asian lineage [32].

While the study was undertaken on samples obtained on day of hospital admission for acute undifferentiated fever [22], it remains unclear as to whether any of the cases were indeed Zika fever. Given that our study investigated the presence of IgG antibodies and that the serum samples were obtained on the day of admission, it is unlikely that admission was as a consequence of Zika fever, although to determine this, far more sensitive and appropriate tools will be required. However, the results from this study suggest that the development of more specific tools, such as neutralization assays to measure neutralizing antibodies is urgently required, especially as our study supports the active transmission of Zika virus in Thailand.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

This work was supported by Mahidol University and the Thailand Research Fund (RTA5780009 and IRG5780009). NW is supported by a Mahidol University Post-Doctoral Fellowship.

References

- [1] Weissenböck H, Hubalek Z, Bakonyi T, Nowotny N. Zoonotic mosquito-borne flaviviruses: worldwide presence of agents with proven pathogenicity and potential candidates of future emerging diseases. *Vet Microbiol* 2010; **140**(3–4): 271–280.
- [2] Dick GW, Kitchen SF, Haddock AJ. Zika virus. I. Isolations and serological specificity. *Trans R Soc Trop Med Hyg* 1952; **46**(5): 509–520.
- [3] Macnamara FN. Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. *Trans R Soc Trop Med Hyg* 1954; **48**(2): 139–145.
- [4] Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections—an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012–2014. *Euro Surveill* 2014; **19**(41). pii=20929, <http://dx.doi.org/10.2807/1560-7917.ES2014.19.41.20929>.
- [5] Alera MT, Hermann L, Tac-An IA, Klungthong C, Rutvisuttinunt W, Manasatienkij W, et al. Zika virus infection, Philippines, 2012. *Emerg Infect Dis* 2015; **21**(4): 722–724.
- [6] Heang V, Yasuda CY, Sovann L, Haddock AD, Travassos da Rosa AP, Tesh RB, et al. Zika virus infection, Cambodia, 2010. *Emerg Infect Dis* 2012; **18**(2): 349–351.
- [7] Kwong JC, Druce JD, Leder K. Zika virus infection acquired during brief travel to Indonesia. *Am J Trop Med Hyg* 2013; **89**(3): 516–517.
- [8] Olson JG, Ksiazek TG, Suhandiman, Triwibowo. Zika virus, a cause of fever in Central Java, Indonesia. *Trans R Soc Trop Med Hyg* 1981; **75**(3): 389–393.
- [9] Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K. First report of autochthonous transmission of Zika virus in Brazil. *Mem Inst Oswaldo Cruz* 2015; **110**(4): 569–572.
- [10] Marchette NJ, Garcia R, Rudnick A. Isolation of Zika virus from *Aedes aegypti* mosquitoes in Malaysia. *Am J Trop Med Hyg* 1969; **18**(3): 411–415.
- [11] Tappe D, Nachtigall S, Kapaun A, Schnitzler P, Gunther S, Schmidt-Chanasit J. Acute Zika virus infection after travel to Malaysian Borneo, September 2014. *Emerg Infect Dis* 2015; **21**(5): 911–913.
- [12] Fonseca K, Meatherall B, Zarra D, Drebot M, MacDonald J, Pabbaraju K, et al. First case of Zika virus infection in a returning Canadian traveler. *Am J Trop Med Hyg* 2014; **91**(5): 1035–1038.
- [13] Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, et al. First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013. *Euro Surveill* 2014; **19**(4); <http://dx.doi.org/10.2807/1560-7917.ES2014.19.4.20685>.
- [14] Haddock AJ, Williams MC, Woodall JP, Simpson DI, Goma LK. Twelve isolations of Zika virus from *Aedes* (*Stegomyia*) *africanus* (Theobald) taken in and above a Uganda forest. *Bull World Health Organ* 1964; **31**: 57–69.
- [15] Li MI, Wong PS, Ng LC, Tan CH. Oral susceptibility of Singapore *Aedes* (*Stegomyia*) *aegypti* (Linnaeus) to Zika virus. *PLoS Negl Trop Dis* 2012; **6**(8): e1792.
- [16] Ledermann JP, Guillaumot L, Yug L, Saweyog SC, Tided M, Machieng P, et al. *Aedes hensilli* as a potential vector of Chikungunya and Zika viruses. *PLoS Negl Trop Dis* 2014; **8**(10): e3188.
- [17] Gourinat AC, O'Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol M. Detection of Zika virus in urine. *Emerg Infect Dis* 2015; **21**(1): 84–86.
- [18] Musso D, Roche C, Nhan TX, Robin E, Teissier A, Cao-Lormeau VM. Detection of Zika virus in saliva. *J Clin Virol* 2015; **68**: 53–55.
- [19] Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Gunther S, et al. Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications. *J Clin Virol* 2015; **63**: 32–35.
- [20] Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, et al. Zika virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia, December 2013. *Eur Surveill* 2014; **19**(9); <http://dx.doi.org/10.2807/1560-7917.ES2014.19.9.20720>.
- [21] Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis* 2008; **14**(8): 1232–1239.
- [22] Thipmontree W, Suputtamongkol Y, Tantibhedhyangkul W, Suttinont C, Wongswat E, Silpasakorn S. Human leptospirosis trends: Northeast Thailand, 2001–2012. *Int J Env Res Public Health* 2014; **11**: 8542–8551.
- [23] Sithisarn P, Suksanpaisan L, Thepparit C, Smith DR. Behavior of the dengue virus in solution. *J Med Virol* 2003; **71**(4): 532–539.
- [24] Thongtan T, Cheepsunthorn P, Chaiworakul V, Rattananarungsan C, Wikan N, Smith DR. Highly permissive infection of microglial cells by Japanese encephalitis virus: a possible role as a viral reservoir. *Microb Infect* 2010; **12**(1): 37–45.
- [25] Wikan N, Sakoonwatanyoo P, Ubol S, Yoksan S, Smith DR. Chikungunya virus infection of cell lines: analysis of the East, central and South African lineage. *PLoS One* 2012; **7**(1): e31102.
- [26] Henchal EA, Gentry MK, McCown JM, Brandt WE. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. *Am J Trop Med Hyg* 1982; **31**(4): 830–836.
- [27] Khamim K, Hattasingh W, Nisalak A, Kaewkungwal J, Fernandez S, Thaisomboonsuk B, et al. Neutralizing dengue antibody in pregnant Thai women and cord blood. *PLoS Negl Trop Dis* 2015; **9**(2): e0003396.
- [28] Pongpaiboon S, Choakouychai B, Boonrueng C, Kutirakan P, Ahandrik S, Leelasiri K, et al. A test production of inactivated mouse brain JE vaccine in Thailand. *Southeast Asian J Trop Med Public Health* 1989; **20**(4): 647–652.
- [29] Olsen SJ, Supawat K, Campbell AP, Anantapreecha S, Liamsuwan S, Tunlayadechanont S, et al. Japanese encephalitis virus remains an important cause of encephalitis in Thailand. *Int J Infect Dis* 2010; **14**(10): e888–892.
- [30] Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. *Cell Host Microbe* 2010; **8**(3): 271–283.
- [31] Nitatpattana N, Kanjanopas K, Yoksan S, Satimai W, Vongba N, Langdatsuwana S, et al. Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand. *Virology* 2014; **11**: 183; <http://dx.doi.org/10.1186/1743-422X-11-183>.
- [32] Pulmanausahakul R, Roytrakul S, Auewarakul P, Smith DR. Chikungunya in Southeast Asia: understanding the emergence and finding solutions. *Int J Infect Dis* 2011; **15**: 671–676.